PLoS ONE · 2010 · 194 citations · 40 references
PharmacyInfectious DiseasesPharmacologyDrug DeliveryImmunopharmacologyInfectious Disease PharmacotherapyAntiviral AgentsAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyNasal Drug DeliveryNasal FormulationsInfluenza Antiviral ResistanceInfluenza Antiviral TherapyInfluenza TreatmentNasal Spray FormulationsNasal SpraysNeuraminidase Inhibitor ResistanceProtective Barrier Function
The 2009 flu pandemic and the appearance of oseltamivir-resistant H1N1 influenza strains highlight the need for treatment alternatives. One such option is the creation of a protective physical barrier in the nasal cavity. In vitro tests demonstrated that iota-carrageenan is a potent inhibitor of influenza A virus infection, most importantly also of pandemic H1N1/2009 in vitro. Consequently, we tested a commercially available nasal spray containing iota-carrageenan in an influenza A mouse infection model. Treatment of mice infected with a lethal dose of influenza A PR8/34 H1N1 virus with iota-carrageenan starting up to 48 hours post infection resulted in a strong protection of mice similar to mice treated with oseltamivir. Since alternative treatment options for influenza are rare, we conclude that the nasal spray containing iota-carrageenan is an alternative to neuraminidase inhibitors and should be tested for prevention and treatment of influenza A in clinical trials in humans.
40
Influenza virus M2 protein has ion channel activity
Lawrence H. Pinto, Leslie J. Holsinger, Robert A. Lamb · Cell · 1992 · 1.2K citations
Structure and mechanism of the M2 proton channel of influenza A virus
Jason R. Schnell, James J. Chou · Nature · 2008 · 1.1K citations
Life Sciences, Biology, Biophysics +12
Masanori Baba, Robert Snoeck, Rudi Pauwels et al. · Antimicrobial Agents and Chemotherapy · 1988 · 542 citations